These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35884158)

  • 21. Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens - The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study.
    Bassetti M; Ariyasu M; Binkowitz B; Nagata TD; Echols RM; Matsunaga Y; Toyoizumi K; Doi Y
    Infect Drug Resist; 2019; 12():3607-3623. PubMed ID: 31819544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Occurrence and characterization of carbapenem-resistant Gram-negative bacilli: A collaborative study of antibiotic-resistant bacteria between Indonesia and Japan.
    Kuntaman K; Shigemura K; Osawa K; Kitagawa K; Sato K; Yamada N; Nishimoto K; Yamamichi F; Rahardjo D; Hadi U; Mertaniasih NM; Kinoshita S; Fujisawa M; Shirakawa T
    Int J Urol; 2018 Nov; 25(11):966-972. PubMed ID: 30253445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and
    Jacobs MR; Abdelhamed AM; Good CE; Rhoads DD; Hujer KM; Hujer AM; Domitrovic TN; Rudin SD; Richter SS; van Duin D; Kreiswirth BN; Greco C; Fouts DE; Bonomo RA
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cefiderocol: a novel siderophore cephalosporin against multi-drug resistant Gram-negative bacilli infections].
    Kuai J; Wang X; Wang H
    Sheng Wu Gong Cheng Xue Bao; 2022 Mar; 38(3):990-1003. PubMed ID: 35355469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.
    Aoki T; Yoshizawa H; Yamawaki K; Yokoo K; Sato J; Hisakawa S; Hasegawa Y; Kusano H; Sano M; Sugimoto H; Nishitani Y; Sato T; Tsuji M; Nakamura R; Nishikawa T; Yamano Y
    Eur J Med Chem; 2018 Jul; 155():847-868. PubMed ID: 29960205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erratum to:
    JAC Antimicrob Resist; 2021 Sep; 3(3):dlab110. PubMed ID: 34466803
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Nakamura R; Ito-Horiyama T; Takemura M; Toba S; Matsumoto S; Ikehara T; Tsuji M; Sato T; Yamano Y
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of combination therapy in the treatment of severe infections caused by carbapenem resistant gram-negatives: a systematic review of clinical studies.
    Savoldi A; Carrara E; Piddock LJV; Franceschi F; Ellis S; Chiamenti M; Bragantini D; Righi E; Tacconelli E
    BMC Infect Dis; 2021 Jun; 21(1):545. PubMed ID: 34107899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: Description of a decade-long trend.
    Balkhair A; Al-Muharrmi Z; Al'Adawi B; Al Busaidi I; Taher HB; Al-Siyabi T; Al Amin M; Hassan KS
    Int J Infect Dis; 2019 Aug; 85():10-15. PubMed ID: 31100418
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Ito A; Sato T; Ota M; Takemura M; Nishikawa T; Toba S; Kohira N; Miyagawa S; Ishibashi N; Matsumoto S; Nakamura R; Tsuji M; Yamano Y
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against
    Carcione D; Siracusa C; Sulejmani A; Migliavacca R; Mercato A; Piazza A; Principe L; Clementi N; Mancini N; Leoni V; Intra J
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens.
    Jorda A; Zeitlinger M
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):777-791. PubMed ID: 33849355
    [No Abstract]   [Full Text] [Related]  

  • 33.
    Mushtaq S; Sadouki Z; Vickers A; Livermore DM; Woodford N
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958717
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In-Vitro Efficacy of Cefiderocol in Carbapenem-Non-Susceptible Gram-Negative Bacilli of Different Genotypes in Sub-Region of North Rhine Westphalia, Germany.
    Ghebremedhin B; Ahmad-Nejad P
    Pathogens; 2021 Sep; 10(10):. PubMed ID: 34684208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug resistance of healthcare-associated pathogenic bacteria and carbapenem-resistant Acinetobacter baumannii homology in the general intensive care unit.
    Liu W; Yang Y; Zhang K; Hai Y; Li H; Jiao Y; Xing H; Xu B; Bai H; Zhao Y; Bao H; Zhang S; Ren W; Yang L; Yang H; Tian J; Wang M; Guo T
    Ann Palliat Med; 2020 Jul; 9(4):1545-1555. PubMed ID: 32692197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.
    Wenzler E; Scoble PJ
    Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Perspectives on Antimicrobial Agents: Cefiderocol.
    McCreary EK; Heil EL; Tamma PD
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0217120. PubMed ID: 34031052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cefiderocol Efficacy in a Real-Life Setting: Single-Centre Retrospective Study.
    Palermo G; Medaglia AA; Pipitò L; Rubino R; Costantini M; Accomando S; Giammanco GM; Cascio A
    Antibiotics (Basel); 2023 Apr; 12(4):. PubMed ID: 37107108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cefiderocol: An Overview of Its
    Yao J; Wang J; Chen M; Cai Y
    Front Med (Lausanne); 2021; 8():741940. PubMed ID: 34950677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.